Visit our Evidence-Based Covid-19 Website and Stay Up to Date with the latest Research.
Volume:2 Issue:3 Number:3 ISSN#:2563-5476
Author Verified
ACE Report #4681
Ace Report Cover General Orthopaedics

Etidronate, alendronate, and reisendronate significantly reduce the risk of hip fracture

Study Type:Meta analysis
OE Level Evidence:2
Journal Level of Evidence:N/A

Efficacy of oral bisphosphonates for preventing hip fracture in disabled patients with neurological diseases: a meta-analysis of randomized controlled trials among the Japanese population

Curr Med Res Opin. 2011 Jun;27(6):1141-8. doi: 10.1185/03007995.2011.570747. Epub 2011 Apr 1

Contributing Authors: J Iwamoto T Takeda H Matsumoto

Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here


Seven randomized controlled trials were included in this meta-analysis which investigated the use of oral bisphosphonates (etidronate, alendronate, or risendronate) in the prevention of hip fracture in the population suffering from neurological diseases, such as amylotrophic lateral sclerosis, stroke, or Parkinson's disease. Included studies were placebo controlled with the exception of one, which...

To view the full report, start your 30-day free trial today

No credit card required

JOIN Forgot Password?

Not sure if you want to join OrthoEvidence?

Access this report without an Account.

Success, an email containing a link to access this report has been sent to your inbox.

CME Image

Continuing Medical Education Credits

You could be earning 0.5 CME credits for each report you read.


Please Login or Join to leave comments.